» Articles » PMID: 19141641

Both TEAD-binding and WW Domains Are Required for the Growth Stimulation and Oncogenic Transformation Activity of Yes-associated Protein

Overview
Journal Cancer Res
Specialty Oncology
Date 2009 Jan 15
PMID 19141641
Citations 113
Authors
Affiliations
Soon will be listed here.
Abstract

The Yes-associated protein (YAP) transcription coactivator is a candidate human oncogene and a key regulator of organ size. It is phosphorylated and inhibited by the Hippo tumor suppressor pathway. TEAD family transcription factors were recently shown to play a key role in mediating the biological functions of YAP. Here, we show that the WW domain of YAP has a critical role in inducing a subset of YAP target genes independent of or in cooperation with TEAD. Mutation of the WW domains diminishes the ability of YAP to stimulate cell proliferation and oncogenic transformation. Inhibition of YAP oncogenic-transforming activity depends on intact serine residues 127 and 381, two sites that could be phosphorylated by the Hippo pathway. Furthermore, genetic experiments in Drosophila support that WW domains of YAP and Yki, the fly YAP homologue, have an important role in stimulating tissue growth. Our data suggest a model in which YAP induces gene expression and exerts its biological functions by interacting with transcription factors through both the TEAD-binding and WW domains.

Citing Articles

Gene therapy for diffuse pleural mesotheliomas in preclinical models by concurrent expression of NF2 and SuperHippo.

Zhu R, Liu X, Zhang X, Zhong Z, Qi S, Jin R Cell Rep Med. 2024; 5(10):101763.

PMID: 39368484 PMC: 11513813. DOI: 10.1016/j.xcrm.2024.101763.


Construction of a prognostic model via WGCNA combined with the LASSO algorithm for stomach adenocarcinoma patients.

Huang Z, Ran W, Wang G Front Genet. 2024; 15:1418818.

PMID: 39170694 PMC: 11335515. DOI: 10.3389/fgene.2024.1418818.


Transcriptional regulation of CYR61 and CTGF by LM98: a synthetic YAP-TEAD inhibitor that targets in-vitro vasculogenic mimicry in glioblastoma cells.

Roy M, Veilleux C, Paquin A, Gagnon A, Annabi B Anticancer Drugs. 2024; 35(8):709-719.

PMID: 38900643 PMC: 11305628. DOI: 10.1097/CAD.0000000000001627.


Focal adhesion kinase-YAP signaling axis drives drug-tolerant persister cells and residual disease in lung cancer.

Haderk F, Chou Y, Cech L, Fernandez-Mendez C, Yu J, Olivas V Nat Commun. 2024; 15(1):3741.

PMID: 38702301 PMC: 11068778. DOI: 10.1038/s41467-024-47423-0.


Role of YAP Signaling in Regulation of Programmed Cell Death and Drug Resistance in Cancer.

Zhou W, Lim A, Edderkaoui M, Osipov A, Wu H, Wang Q Int J Biol Sci. 2024; 20(1):15-28.

PMID: 38164167 PMC: 10750275. DOI: 10.7150/ijbs.83586.